Alnylam Pharmaceuticals Inc


Prices are adjusted according to historical splits.

Alnylam Pharmaceuticals Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$23.91 billion
Book Value:
Revenue TTM:
$1.04 billion
Operating Margin TTM:
Gross Profit TTM:
$868.60 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Alnylam Pharmaceuticals Inc had its IPO on 2004-05-28 under the ticker symbol ALNY.

The company operates in the Healthcare sector and Biotechnology industry. Alnylam Pharmaceuticals Inc has a staff strength of 2,002 employees.

Stock update

Shares of Alnylam Pharmaceuticals Inc opened at $190.88 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $188.81 - $195.8, and closed at $193.67.

This is a +2.65% increase from the previous day's closing price.

A total volume of 344,188 shares were traded at the close of the day’s session.

In the last one week, shares of Alnylam Pharmaceuticals Inc have increased by +4.17%.

Alnylam Pharmaceuticals Inc's Key Ratios

Alnylam Pharmaceuticals Inc has a market cap of $23.91 billion, indicating a price to book ratio of 142.9249 and a price to sales ratio of 29.3666.

In the last 12-months Alnylam Pharmaceuticals Inc’s revenue was $1.04 billion with a gross profit of $868.60 million and an EBITDA of $-740604032. The EBITDA ratio measures Alnylam Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alnylam Pharmaceuticals Inc’s operating margin was -75.68% while its return on assets stood at -13.65% with a return of equity of -526.14%.

In Q4, Alnylam Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 29.6%.

Alnylam Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-9.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.49. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alnylam Pharmaceuticals Inc’s profitability.

Alnylam Pharmaceuticals Inc stock is trading at a EV to sales ratio of 28.6379 and a EV to EBITDA ratio of -29.4227. Its price to sales ratio in the trailing 12-months stood at 29.3666.

Alnylam Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$3.55 billion
Total Liabilities
$767.92 million
Operating Cash Flow
Capital Expenditure
$55.64 million
Dividend Payout Ratio

Alnylam Pharmaceuticals Inc ended 2023 with $3.55 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.55 billion while shareholder equity stood at $-158223000.00.

Alnylam Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $767.92 million in other current liabilities, 1240000.00 in common stock, $-6569349000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $866.39 million and cash and short-term investments were $2.16 billion. The company’s total short-term debt was $41,967,000 while long-term debt stood at $1.02 billion.

Alnylam Pharmaceuticals Inc’s total current assets stands at $2.69 billion while long-term investments were $0 and short-term investments were $1.30 billion. Its net receivables were $237.96 million compared to accounts payable of $98.09 million and inventory worth $128.96 million.

In 2023, Alnylam Pharmaceuticals Inc's operating cash flow was $-139911000.00 while its capital expenditure stood at $55.64 million.

Comparatively, Alnylam Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Alnylam Pharmaceuticals Inc stock is currently trading at $193.67 per share. It touched a 52-week high of $242.97 and a 52-week low of $242.97. Analysts tracking the stock have a 12-month average target price of $245.92.

Its 50-day moving average was $198.76 and 200-day moving average was $209.04 The short ratio stood at 7.06 indicating a short percent outstanding of 0%.

Around 51.8% of the company’s stock are held by insiders while 9851.9% are held by institutions.

Frequently Asked Questions About Alnylam Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Alnylam Pharmaceuticals Inc is ALNY

The IPO of Alnylam Pharmaceuticals Inc took place on 2004-05-28

Similar Industry Stocks (Biotechnology)

Last Price
Shanthi Gears Limited (SHANTIGEAR)

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.


675 West Kendall Street, Cambridge, MA, United States, 02142